Program
SYN023
A development code. Also written as “recombinant anti-rabies human monoclonal antibody injection (SYN023)”.
Its studies are mostly in Rabies, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Synermore Biologics (Suzhou) | 30 open or running | phase 3since Nov 16, 2020 | May 10, 2020 | none ahead |
| Synermore Biologics | 20 open or running | phase 2since Nov 1, 2016 | Nov 1, 2016 | none ahead |
Also a collaborator on its studies: simoon-record-pharma-information-consulting-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 1, 2016First study: phase 2 study in Human RabiesNew to Synermore BiologicsSynermore Biologics · NCT02956746 · 164 enrolled · United States
- May 16, 2019Phase 2 study in RabiesSynermore Biologics · NCT03961555 · 448 enrolled · United States, Philippines
- May 10, 2020Synermore Biologics (Suzhou)'s first study: phase 2 study in ZoonosesNew to Synermore Biologics (Suzhou)Synermore Biologics (Suzhou) · NCT04495569 · 33 enrolled · China
- Nov 16, 2020Phase 3 study in RabiesSynermore Biologics (Suzhou) · NCT04644484 · 1,000 enrolled · China
- Dec 24, 2025Phase 1 study in RabiesSynermore Biologics (Suzhou) · NCT07342257 · 108 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07342257Rabies · China | 1 | Completed | Synermore Biologics (Suzhou) | May 9, 2025 | 108 |
| NCT04644484Rabies · China | 3 | Completed | Synermore Biologics (Suzhou) | Jun 24, 2022 | 1,000 |
| NCT04495569Zoonoses · China | 2 | Completed | Synermore Biologics (Suzhou) | Jun 20, 2019 | 33 |
| NCT03961555Rabies · United States, Philippines | 2 | Completed | Synermore Biologics | Dec 23, 2021 | 448 |
| NCT02956746Human Rabies · United States | 2 | Completed | Synermore Biologics | Dec 2017 | 164 |
How it is read
Names in the registry
- “SYN023”, 4 entries
- “recombinant anti-rabies human monoclonal antibody injection (SYN023)”, 1 entry
Codes read as this program: SYN023.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.